Evercore ISI analyst Liisa Bayko projects Madrigal's MASH dr...
Evercore ISI analyst Liisa Bayko projects Madrigal's MASH drug sales to exceed $2 billion by 2029, despite competition from anti-obesity medications. The FDA's approval of a MASH drug could boost awareness and patient demand.
Madrigal's Stock Surges as FDA Approves First Drug for Liver Disease MASH
免責聲明：以上信息不代表Moomoo Technologies Inc.("MTI")的任何立場，不構成與MTI及其關聯公司的任何投資建議。
更多信息
評論
登錄發表評論
